Chromone bisindole derivative as well as preparation method and application thereof
By synthesizing chromone bisindole derivatives, the problem of insufficient existing tumor treatment methods has been solved, providing a highly efficient anti-tumor drug option, especially with significant inhibitory effects on leukemia, cervical cancer and gastric cancer, and suitable for large-scale preparation and drug screening.
Patent Information
- Application Number
- CN202610404213.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-30
- Publication Date
- 2026-05-05
AI Technical Summary
Current cancer treatments mainly rely on surgery, radiotherapy, and chemotherapy, lacking efficient drug treatment options, especially in the development of anti-tumor drugs based on natural compounds.
Using chromone bisindole derivatives as antitumor drugs, chromone ketone esters with different substitutions on the benzene ring were added to indole in an addition reaction, with p-toluenesulfonic acid as a catalyst and dichloromethane as a solvent, to synthesize chromone bisindole derivatives with antitumor activity.
Twenty-one bisindole derivatives with novel structures, simple synthesis, and high yield were provided, which significantly inhibited the growth of leukemia, cervical cancer, and gastric cancer cells. Some compounds showed better activity than the positive control cisplatin, making them suitable for large-scale preparation and drug screening.
Smart Images

Figure EL05YHZA8DIGR9Y4WNTSST8OKHPOMNVAKSMUHJ11 
Figure FV58XZMZNJMHQVAJBKANPCEW9NRR7IR6OC3PY2WG 
Figure GEOC1HPW2P33AFRANM9VJWO0RG9DDJGQ8AYLBXSN
Abstract
Description
Technical Field
[0001] This invention relates to the fields of medicinal chemistry and oncology pharmacology, and in particular to a chromone bisindole derivative, its preparation method, and its application. Background Technology
[0002] Cancer is the second leading health threat globally, second only to cardiovascular disease in terms of disease burden. According to the latest statistics from the International Agency for Research on Cancer (IARC) of the World Health Organization, approximately 20 million new cancer cases were diagnosed worldwide in 2022, and this number is projected to exceed 35 million by 2050, representing an increase of 77%. Currently, clinical cancer treatment primarily relies on surgical resection, radiotherapy, and chemotherapy. Against this backdrop, research into drug therapies continues to deepen, playing an increasingly important role in comprehensive cancer treatment systems.
[0003] Chromones, as oxygen-containing heterocyclic compounds of the benzo-γ-pyranone class, have derivatives widely distributed in traditional medicinal plant resources, particularly in plants of the genera *Saposhnikovia* (Apiaceae) and *Aquilaria* (Thymelaeaceae). These compounds are important active ingredients due to their unique benzo-γ-pyranone skeleton. Notably, chromones are not only widely found in medicinal plants but are also common components of the human diet, a natural attribute that endows them with unique advantages for drug development. Modern pharmacological studies have shown that these compounds possess various biological activities, with anti-tumor effects being particularly prominent. They have been proven to exert anti-cancer effects through multiple mechanisms, including regulating the cell cycle, inducing tumor cell apoptosis, and inhibiting angiogenesis. Based on these characteristics, innovative structural modifications targeting the chromone core, and systematically conducting targeted synthesis and anti-tumor activity evaluation of novel derivatives, not only help elucidate the intrinsic laws of structure-activity relationships but also provide lead compounds for the development of new anti-tumor drugs based on natural products. This has significant scientific value for promoting the modernization of traditional Chinese medicine research and the innovation of targeted cancer therapy strategies. Summary of the Invention
[0004] The purpose of this invention is to provide a chromone bisindole derivative, a simple and efficient preparation method thereof, and its application in antitumor drugs.
[0005] To achieve the objectives of this invention, the following technical solutions and steps are employed: This invention provides a chromone bisindole derivative having a structure as shown in general formula (I): (I), Wherein, the R substituent is selected from phenyl, 8-methylphenyl, 7-methylphenyl, 6-methylphenyl, 7-methoxyphenyl, 5-methoxyphenyl, 8-fluorophenyl, 7-fluorophenyl, 6-fluorophenyl, 5-fluorophenyl, 8-chlorophenyl, 7-chlorophenyl, 6-chlorophenyl, 5-chlorophenyl, 8-bromophenyl, 7-bromophenyl, 6-bromophenyl, 6-nitrophenyl, 6,8-dimethylphenyl, 6,7-dimethylphenyl, and naphthyl, and the specific structure corresponds one-to-one with the following structural formulas 3a-3u: This invention provides a method for preparing chromone bisindole derivatives. Using chromone esters with different benzene ring substitutions as raw materials, the 3-position of these esters is modified. Dichloromethane (DCM) is used as a solvent, p-toluenesulfonic acid (TsOH) as a catalyst, and an addition reaction is performed with indole to obtain the chromone bisindole derivatives. The specific steps are as follows: 0.3 mmol of chromone esters with different benzene ring substitutions, 0.9 mmol of indole, and 0.03 mmol of TsOH were added sequentially to a 10 mL reaction flask, followed by 3 mL of DCM. The mixture was stirred at room temperature for 16 hours. Thin-layer chromatography was used to monitor the reaction during the reaction. After the reaction was completed, the chromone bisindole derivatives were purified by silica gel column chromatography. The chromone esters with different substitutions on the benzene ring refer to compounds 1a-1u, which are substituted with phenyl, 8-methylphenyl, 7-methylphenyl, 6-methylphenyl, 7-methoxyphenyl, 5-methoxyphenyl, 8-fluorophenyl, 7-fluorophenyl, 6-fluorophenyl, 5-fluorophenyl, 8-chlorophenyl, 7-chlorophenyl, 6-chlorophenyl, 5-chlorophenyl, 8-bromophenyl, 7-bromophenyl, 6-bromophenyl, 6-nitrophenyl, 6,8-dimethylphenyl, 6,7-dimethylphenyl, and naphthyl, respectively. The synthetic route is as follows: .
[0006] The molar ratio of chromone esters with different benzene ring substitutions, indole, and TsOH in this invention is chromone esters with different benzene ring substitutions: indole: TsOH = 1:3:0.1.
[0007] The solvent system monitored in this invention is a mixture of PE and EA at a volume ratio of 2:1.
[0008] The eluent for silica gel column chromatography purification described in this invention is V. PE With V EA A mixture of 4:1.
[0009] This invention provides the application of chromone bisindole derivatives in the preparation of antitumor drugs.
[0010] The antitumor drug described in this invention is used to treat leukemia, cervical cancer, or gastric cancer.
[0011] Beneficial effects of this invention: 1. This invention provides 21 chromone bisindole derivatives with novel structures, simple synthetic routes, mild conditions, and high yields, making them suitable for large-scale preparation.
[0012] 2. The chromone bisindole derivatives provided by this invention exhibit significant antitumor effects. Experimental results show that in K562 chronic myeloid leukemia cells, one compound (3q) of the chromone bisindole derivatives showed inhibitory effects on cell growth similar to the positive control cisplatin, with compound 3q showing superior inhibitory activity compared to the positive control (IC50). 50 =14.05±0.95µM). In HeLa cell experiments, seven compounds (3c, 3g, 3h, 3l, 3m, 3o, 3p) showed inhibitory activity close to that of the positive control cisplatin, among which compound 3m (IC50) was the most effective. 50 The inhibitory activity of compounds 3c, 3h, and 3l (13.95±0.98µM) was higher than that of the positive control, and the activity was the best. In the gastric adenocarcinoma AGS assay, the inhibitory effects of compounds 3c, 3h, and 3l on cells were similar to those of the positive control cisplatin, with compound 3h exhibiting the highest activity (IC50 ± 0.98µM). 50 =6.70±0.37µM).
[0013] This indicates that, based on the parent nucleus, halogen (Br, Cl, F) substituents are key factors in enhancing activity, and different halogens and substitution positions have varying effects on activity and cell selectivity. Specifically, bromine substitution: compound 3q (for K562, IC...) 50 =14.05μM), 3o (for HeLa, IC 50 The activity of compound 3m (19.39 μM) was superior to that of cisplatin (K562: 14.85 μM; HeLa: 19.87 μM), indicating that bromine substitution can enhance the inhibitory activity against K562 and HeLa cells. Chlorine substitution: Compound 3m showed better inhibitory activity against HeLa cells at IC50 levels. 50 =13.95μM, the highest activity against HeLa cells among all tested compounds, indicating that chlorine substitution in this structure has a particularly significant "synergistic effect" on HeLa cells. Fluorine substitution: the IC50 of compound 3h on AGS cells. 50 =6.70μM, which is far superior to cisplatin (AGS: 10.78μM), demonstrating the "selective synergistic effect" of fluorine substitution on AGS cells.
[0014] 3. The preparation method of this invention is simple to operate, has a short reaction time, high yield, readily available and stable raw materials, and wide applicability. It can provide compound sources for bioactivity screening and has important application value for drug screening and the pharmaceutical industry. Attached Figure Description
[0015] Figure 1 : Compound 3h 1 HNMR.
[0016] Figure 2 : Compound 3h 13 CNMR.
[0017] Figure 3 : Compound 3h 19 FNMR. Detailed Implementation
[0018] The present invention will be described in detail below with reference to specific embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but do not limit the present invention in any way. For those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention, and these all fall within the protection scope of the present invention.
[0019] Example 1: Synthesis of chromone bisindole compounds 3a-3u (1) Synthesis of chromone bisindole compound 3a: Compound 1a (0.3 mmol, 1.0 equiv), indole (0.9 mmol, 3 equiv), and TsOH (0.03 mmol, 0.1 equiv) were added sequentially to a 10 mL reaction flask, followed by 3 mL of DCM. The mixture was stirred at room temperature for 16 hours. Thin-layer chromatography (TLC) was used to monitor the reaction, with a PE / EA mixture at a volume ratio of 2:1 as the solvent. After the reaction was complete, the product was purified by silica gel column chromatography using a PE / EA mixture at a volume ratio of 4:1 as the eluent. The final product was a white solid, 3a, with a yield of 49%.
[0020] (2) Synthesis of chromone bisindole compounds 3b-3u: The preparation method is the same as that of compound 3a, and the feed ratio is the same as that of compound 3a, which can yield compound 3b-3u. Example 2
[0021] Compound 3a, white solid, melting point: 176.6 - 177.5 °C; yield 49%. Results of NMR and high-resolution mass spectrometry measurements are as follows: 1H NMR (400 MHz, DMSO–d6) δ 11.08 (s, 1H), 11.07 (s, 1H), 8.03– 8.01 (m, 1H), 7.96 (s, 1H), 7.79 – 7.74 (m, 1H), 7.59 – 7.57 (m, 1H), 7.47– 7.43 (m, 1H), 7.37 – 7.35 (m, 2H), 7.19 – 7.17 (m, 4H), 7.01 – 6.97 (m,2H), 6.80 – 6.76 (m, 2H), 3.58 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 175.44,171.86, 155.57, 154.66, 136.60, 134.17, 126.47, 125.78, 125.37, 125.28,123.38, 120.99, 120.58, 118.53, 118.35, 112.12, 111.72, 51.65, 50.68. HRMS(ESI): Exact mass calcd for: C 28 H 20 N₂O₄ [M+Na] + : 471.1315, found: 471.1314. The structure is as follows: .
[0022] Compound 3b is a yellowish-brown solid with a melting point of 246.1 - 247.2 °C and a yield of 35%. The results of NMR and high-resolution mass spectrometry analyses are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.07 (s, 1H), 11.06 (s, 1H), 7.91 (s, 1H), 7.87 – 7.85 (m, 1H), 7.63 – 7.61 (m, 1H), 7.36 – 7.34 (m, 3H),7.16 – 7.11 (m, 4H), 7.00 – 6.96 (m, 2H), 6.78 – 6.74 (m, 2H), 3.59 (s, 3H),2.37 (s, 3H). 13C NMR (100 MHz, DMSO–d6) δ 175.72, 171.88, 154.42, 154.05,136.59, 134.68, 127.45, 126.22, 125.91, 125.86, 124.84, 123.31, 122.88,120.93, 120.56, 118.51, 112.31, 111.68, 51.66, 50.65, 14.98. HRMS (ESI): Exact mass calcd for: C 29 H 22 N₂O₄ [M+Na] + : 485.1472, found: 485.1477. .
[0023] Compound 3c: yellow solid, melting point: 232.2 - 233.6 ℃; yield 45%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.06 (s, 1H),11.05 (s, 1H), 7.90– 7.87 (m, 2H), 7.40 (s, 1H), 7.35 (d, J = 8 Hz, 2H), 7.28 (d, J = 6.4 Hz,1H), 7.15 (d, J = 9.2 Hz, 4H), 7.00 – 6.96 (m, 2H), 6.78 – 6.75 (m, 2H), 3.58(s, 3H), 2.43 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 174.58, 172.57, 156.45,154.38, 145.12, 136.08, 126.75, 126.36, 125.82, 125.70, 125.09, 121.20,120.97, 120.55, 118.49, 117.83, 112.24, 111.70, 51.62, 50.18, 20.26. HRMS(ESI): Exact mass calcd for: C 29 H 22 N₂O₄ [M+Na] + : 485.1472, found: 485.1471. .
[0024] Compound 3d: pale yellow solid, melting point: 199.0 - 200.2 ℃; yield 43%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.07 (s, 1H), 11.06 (s, 1H), 7.90 (s, 1H), 7.81 – 7.80 (m, 1H), 7.59 – 7.56 (m, 1H), 7.48 – 7.86 (m, 1H),7.36 – 7.34 (m, 2H), 7.18 – 7.14 (m, 4H), 7.00 – 6.96 (m, 2H), 6.79 – 6.75(m, 2H), 3.58 (s, 3H), 2.39 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 177.56,170.18, 156.33, 153.83, 139.01, 135.66, 135.37, 128.68, 126.30, 126.16,125.00, 123.56, 121.92, 121.02, 118.96, 118.58, 112.72, 112.16, 52.08, 51.11,22.29. HRMS (ESI): Exact mass calcd for: C 29 H 22 N₂O₄ [M+Na] + : 485.1472, found:485.1467. .
[0025] Compound 3e: Orange-red solid, melting point: 150.3 - 151.5 ℃; yield 33%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.06 (s, 1H), 11.05 (s, 1H), 7.91 – 7.86 (m, 2H), 7.36 – 7.34 (m, 2H), 7.17 – 7.15 (m, 4H), 7.06 – 7.01(m, 2H), 7.00 – 6.96 (m, 2H), 6.79 – 6.75 (m, 2H), 3.85 (s, 3H), 3.57 (s,3H). 13C NMR (100 MHz, DMSO–d6) δ 174.71, 171.87, 163.68, 157.40, 154.08,136.54, 126.62, 126.31, 125.75, 125.54, 120.96, 120.45, 118.38, 117.24,114.69, 112.22, 111.61, 100.33, 55.98, 51.51, 50.50. HRMS (ESI): Exact masscalcd for: C 29 H 22 N₂O₅ [M+Na] + Found: 501.1421, Found: 501.1420. .
[0026] Compound 3f: golden yellow solid, melting point: 222.5 - 223.8 ℃; yield 54%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.04 (s, 1H), 11.03 (s, 1H), 7.77 (s, 1H), 7.65 – 7.61 (m, 1H), 7.35 – 7.33 (m, 2H), 7.17 – 7.15 (m, 4H),7.06 – 7.03 (m, 1H), 6.99 – 6.95 (m, 2H), 6.93 – 6.91 (m, 1H), 6.79 – 6.75(m, 2H), 3.80 (s, 3H), 3.56 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 174.36,171.92, 159.40, 157.48, 152.48, 136.54, 134.24, 126.67, 126.57, 125.77,121.04, 120.48, 118.46, 113.83, 112.17, 111.68, 109.70, 106.84, 56.03, 51.53,50.51. HRMS (ESI): Exact mass calcd for: C 29 H 22 N₂O₅ [M+Na] + : 501.1421, Found:501.1421. .
[0027] Compound 3g: orange-yellow solid, melting point: 177.5 - 178.6 ℃; yield 43%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.09 (s, 1H), 11.08 (s, 1H), 8.03 (s, 1H), 7.82 – 7.80 (m, 1H), 7.76 – 7.71 (m, 1H), 7.46 – 7.41 (m, 1H), 7.37 – 7.35 (m, 2H), 7.19 – 7.17 (m, 4H), 7.01 – 6.97 (m, 2H), 6.80 – 6.77(m, 2H), 3.59 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 174.63 (d, J = 2.3 Hz),171.69, 154.44, 150.51 (d, J = 249.5 Hz), 144.26 (d, J = 11.2 Hz), 136.61,126.54, 126.26, 125.73, 125.43 (d, J = 31.6 Hz), 125.34, 120.99, 120.61,119.80 (d, J = 16.2 Hz).118.59, 111.87, 111.73, 79.19, 51.71, 50.71. HRMS(ESI): Exact mass calcd for: C 28 H 19 FN2O4 [M+Na] + Found: 489.1221. .
[0028] Compound 3h: pale yellow solid, melting point: 205.9 - 206.4 ℃; yield 46%; results of NMR and high-resolution mass spectrometry are as follows: 1H NMR (400 MHz, DMSO–d6) δ 11.08 (s, 1H), 11.07 (s, 1H), 8.09 – 8.04 (m, 1H), 7.95 (s, 1H), 7.56 – 7.54 (m, 1H), 7.36 – 7.34 (m, 3H), 7.18 – 7.16 (m, 4H), 7.00 – 6.96 (m, 2H), 6.80 – 6.76 (m, 2H), 3.58 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 175.13, 172.20, 165.39 (d, J = 252.2 Hz), 157.09 (d, J = 14.3 Hz), 155.40, 137.05, 128.65 (d, J = 10.9 Hz), 126.95, 126.35,126.18, 121.42, 121.01 (d, J = 4.0 Hz), 118.99, 114.59 (d, J = 23.2 Hz),112.42, 112.18, 105.55 (d, J = 25.6 Hz), 79.64, 52.12, 51.06. HRMS (ESI):Exact mass calcd for: C 28 H 19 FN2O4 [M+Na] + Found: 489.1221, Found: 489.1220. .
[0029] Compound 3i: yellow solid, melting point: 270.5 - 271.8 ℃; yield 42%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.09 (s, 1H), 11.08 (s, 1H), 7.99 (s, 1H), 7.70 – 7.68 (m, 3H), 7.37 – 7.34 (m, 2H), 7.18 – 7.15 (m, 4H), 7.01– 6.97 (m, 2H), 6.80 – 6.76 (m, 2H), 3.58 (s, 3H). 13C NMR (100 MHz, DMSO–d6)δ 174.81 (d, J = 1.8 Hz), 171.71, 158.91 (d, J = 242.6 Hz), 154.97, 152.04,136.58, 126.50, 125.71, 125.15, 124.44 (d, J = 7.0 Hz), 122.39 (d, J = 25.2Hz), 121.22 (d, J = 8.s4 Hz), 120.93, 120.57, 118.53, 111.91, 111.71, 109.74(d, J = 23.5 Hz), 56.03, 51.67. HRMS (ESI): Exact mass calcd for: C 28 H 19 FN₂O₄[M+Na] + Found: 489.1221, Found: 489.1220. .
[0030] Compound 3j: yellow solid, melting point: 200.6 - 201.8 ℃; yield 45%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.08 (s, 1H), 11.07 (s, 1H), 8.09– 8.06 (m, 1H), 7.96 (s, 1H), 7.57 – 7.54 (m, 1H), 7.36 – 7.34 (m, 3H), 7.18– 7.16 (m, 4H), 7.00 – 6.97 (m, 2H), 6.80 – 6.76 (m, 2H), 3.58 (s, 3H). 13C NMR(100 MHz, DMSO–d6) δ 173.70, 171.71, 159.80 (d, J = 260.6 Hz), 156.63 (d, J =3.0 Hz), 153.88, 136.59, 134.56 (d, J = 10.7 Hz), 126.64, 126.55, 125.74,120.98, 120.57, 118.54, 114.50 (d, J = 4.2 Hz), 113.67 (d, J = 10.0 Hz), 111.94 (d, J = 20.3 Hz), 111.92, 111.73, 51.66, 50.56. HRMS (ESI): Exact masscalcd for: C 28 H 19 FN2O4 [M+Na] + Found: 489.1221, Found: 489.1225. .
[0031] Compound 3K: golden yellow solid, melting point: 204.9 - 205.5 °C; yield 51%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.09 (s, 1H), 11.08 (s, 1H), 8.02 (s, 1H), 7.99 – 7.94 (m, 2H), 7.48 – 7.44 (m, 1H), 7.36 – 7.34 (m, 2H), 7.19 – 7.15 (m, 4H), 7.01 – 6.97 (m, 2H), 6.80 – 6.76 (m, 2H), 3.59 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 174.93, 171.64, 154.67, 151.13, 136.60, 134.20,126.45, 126.28, 125.80, 125.76, 124.81, 124.41, 121.91, 120.94, 120.59,118.57, 111.86, 111.71, 51.72, 50.68. HRMS (ESI): Exact mass calcd for:C 28 H 19 ClN2O4 [M+Na]+ : 505.0926, Found: 505.0922. .
[0032] Compound 3l: white solid, melting point: 262.3 - 263.5 °C; yield 35%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.08 (s, 1H), 11.07 (s, 1H), 8.02– 8.00 (m, 1H), 7.93 (s, 1H), 7.80 (s, 1H), 7.52 – 7.50 (m, 1H), 7.36 – 7.34(m, 2H), 7.17 – 7.15 (m, 4H), 7.00 – 6.96 (m, 2H), 6.79 – 6.76 (m, 2H), 3.58(s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 174.81, 171.72, 155.83, 154.85, 138.54,136.60, 127.21, 126.46, 126.16, 126.01, 125.74, 122.21, 120.95, 120.61,118.56, 118.34, 111.95, 111.74, 51.71, 50.66. HRMS (ESI): Exact mass calcdfor: C 28 H 19 ClN2O4 [M+Na] + : 505.0926, Found: 505.0920. .
[0033] Compound 3m: golden yellow solid, melting point: 241.6 - 242.8 ℃; yield 44%; results of NMR and high-resolution mass spectrometry are as follows: 1H NMR (400 MHz, DMSO–d6) δ 11.09 (s, 1H), 11.08 (s, 1H), 7.98 (s, 1H), 7.96-7.95 (m, 1H), 7.82-7.79 (m, 1H), 7.66-7.64 (m, 1H), 7.37-7.35 (m, 2H), 7.19-7.15 (m, 4H), 7.01-6.96 (m, 2H), 6.79-6.75 (m, 2H), 3.59(s, 3H). 13 C NMR (100 MHz, DMSO-d6)-δ-174.44, 171.69, 155.02, 154.18, 136.61,134.10, 129.91, 126.48, 125.90, 125.74, 124.43, 124.25, 120.94, 120.60,118.56, 111.91, 111.73, 51.71, 50.70. HRMS (ESI): Exact mass calcd for:C 28 H 19 ClN2O4 [M+Na] + : 505.0926, Found: 505.0925. .
[0034] Compound 3n: white solid, melting point: 248.7 - 249.6 ℃; yield 47%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.08 (s, 1H), 11.07 (s, 1H), 7.90 (s, 1H), 7.70 – 7.66 (m, 1H), 7.55 – 7.52 (m, 1H), 7.47 – 7.45 (m, 1H), 7.36– 7.34 (m, 2H), 7.20 – 7.16 (m, 4H), 7.00 – 6.96 (m, 2H), 6.80 – 6.76 (m,2H), 3.59 (s, 3H). 13C NMR (100 MHz, DMSO–d6) δ 174.18, 171.71, 157.24,153.55, 136.58, 133.74, 131.74, 128.04, 126.73, 126.54, 125.74, 121.00,120.55, 120.06, 118.52, 118.03, 111.98, 111.71, 51.62, 50.69. HRMS (ESI): Exact mass calcd for: C 28 H 19 ClN2O4 [M+Na] + Found: 505.0926, Found: 505.0928. .
[0035] Compound 3o: white solid, melting point: 218.4 - 219.4 °C; yield 45%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.08 (s, 1H), 11.07 (s, 1H), 8.11– 8.09 (m, 1H), 8.03 – 7.99 (m, 2H), 7.42 – 7.38 (m, 1H), 7.36 – 7.34 (m,2H), 7.18 – 7.14 (m, 4H), 7.00 – 6.96 (m, 2H), 6.79 – 6.76 (m, 2H), 3.59 (s,3H). 13 C NMR (100 MHz, DMSO–d6) δ 175.01, 171.65, 154.78, 152.07, 150.64,137.40, 136.60, 126.39, 126.26, 125.79, 125.09, 124.76, 120.92, 120.60,118.57, 111.90, 111.70, 111.06, 51.72, 50.69. HRMS (ESI): Exact mass calcdfor: C 28 H 19 BrN2O4 [M+Na] + : 549.0420, Found: 549.0422. .
[0036] Compound 3p: white solid, melting point: 299.4 - 300.4 ℃; yield 59%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.08 (s, 1H), 11.07 (s, 1H), 7.94– 7.92 (m, 3H), 7.65 – 7.62 (m, 1H), 7.36 – 7.34 (m, 2H), 7.18 – 7.15 (m,4H), 7.00 – 6.96 (m, 2H), 6.79 – 6.75 (m, 2H), 3.58 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 174.91, 171.69, 155.78, 154.76, 136.59, 128.74, 127.25, 127.19,126.44, 126.16, 125.73, 122.47, 121.25, 120.93, 120.58, 118.54, 111.94,111.71, 51.69, 50.66. HRMS (ESI): Exact mass calcd for: C 28 H 19 BrN2O4 [M+Na] + :549.0420, Found: 549.0423. .
[0037] Compound 3q: white solid, melting point: 309.3 - 310.0 ℃; yield 41%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.08 (s, 1H), 11.07 (s, 1H), 8.09 – 8.08 (m, 1H), 7.97 (s, 1H), 7.95 – 7.92 (m, 1H), 7.61 – 7.59 (m, 1H), 7.36 – 7.34 (m, 2H), 7.18 – 7.14 (m, 4H), 7.00 – 6.96 (m, 2H), 6.79 – 6.75 (m, 2H), 3.58 (s, 3H). 13C NMR (100 MHz, DMSO–d6) δ 174.30, 171.66, 155.00, 154.53,136.82, 136.59, 127.38, 126.44, 125.98, 125.73, 124.81, 121.10, 120.92,120.59, 118.54, 117.82, 111.89, 111.71, 51.69, 50.69. HRMS (ESI): Exact masscalcd for: C 28 H 19 BrN2O4 [M+Na] + : 549.0420, Found: 549.0420. .
[0038] Compound 3r: a yellow oily substance, yield 52%; results of NMR and high-resolution mass spectrometry tests are as follows: 1 HNMR (400 MHz, DMSO–d6) δ 11.89 (s, 1H), 11.10 (s, 1H), 8.72 – 8.71 (m, 1H), 8.56 – 8.53 (m, 1H), 8.06 (s, 1H), 7.88 – 7.86 (m, 1H), 7.36 – 7.34 (m, 2H), 7.20 – 7.16 (m, 4H), 7.01 – 6.97 (m, 2H), 6.80 – 6.76 (m, 2H), 3.60 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 174.06, 171.55, 159.00, 153.34, 143.89, 137.08,128.42, 126.55, 125.71, 123.34, 121.55, 120.92, 120.82, 120.68, 118.64,117.76, 112.20, 111.68, 51.82, 50.72. HRMS (ESI): Exact mass calcd for:C 28 H 19 N3O6 [M+Na] + Found: 516.1166, Found: 516.1164. .
[0039] Compound 3s: Orange-yellow solid, melting point: 241.9 - 242.6 ℃; yield 45%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO–d6) δ 11.05 (s, 1H), 11.04 (s, 1H), 7.85 (s, 1H), 7.65 – 7.64 (m, 1H), 7.47 – 7.46 (m, 1H), 7.35 – 7.33 (m, 2H),7.14 – 7.13 (m, 2H), 7.10 – 7.08 (m, 2H), 6.99 – 6.95 (m, 2H), 6.77 – 6.73(m, 2H), 3.58 (s, 3H), 2.36 (s, 3H), 2.35 (s, 3H). 13 C NMR (100 MHz, DMSO–d6)δ 175.68, 171.93, 154.24, 152.37, 136.57, 135.85, 134.26, 127.14, 126.09,125.97, 125.81, 123.06, 122.18, 120.93, 120.54, 118.48, 112.45, 111.66,51.64, 50.62, 20.44, 14.90. HRMS (ESI): Exact mass calcd for: C 30 H 24 N₂O₄ [M+Na] + : 499.1628, found: 499.1629. .
[0040] Compound 3t: yellow solid, melting point: 247.2 - 248.1 ℃; yield 50%; results of NMR and high-resolution mass spectrometry are as follows: 1H NMR (400 MHz, DMSO–d6) δ 11.05 (s, 1H),11.04 (s, 1H), 7.82(s, 1H), 7.74 (s, 1H), 7.38 (s, 1H), 7.35 (s, 1H), 7.33 (s, 1H), 7.14 – 7.13(m, 3H), 7.11 (s, 1H), 6.99 – 6.95 (m, 2H), 6.77 – 6.73 (m, 2H), 3.57 (s,3H), 2.33 (s, 3H), 2.29 (s, 3H). 13 C NMR (100 MHz, DMSO–d6) δ 175.23, 171.96,154.17, 154.12, 144.32, 136.57, 134.36, 126.23, 125.87, 125.70, 124.76,121.27, 120.97, 120.52, 118.45, 118.11, 112.40, 111.66, 51.59, 50.61, 19.81,18.88. HRMS (ESI): Exact mass calcd for: C 30 H 24 N₂O₄ [M+Na] + : 499.1628, Found: 499.1629. .
[0041] Compound 3u: yellow solid, melting point: 255.4 - 256.6 ℃; yield 60%; results of NMR and high-resolution mass spectrometry are as follows: 1 H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 11.10 (s, 1H), 8.35- 8.32 (m, 1H), 8.08 - 8.05 (m, 2H), 7.96 - 7.94 (m, 1H), 7.89 - 7.87 (m,1H), 7.78 - 7.75 (m, 1H), 7.72 - 7.68 (m, 1H), 7.38 - 7.36 (m, 2H), 7.22 (s,2H), 7.18 - 7.16 (m, 2H), 7.00 - 6.96 (m, 2H), 6.77 - 6.74 (m, 2H), 3.61 (s, 3H). 13C NMR (100 MHz, DMSO-d6) δ 175.20, 168.42, 154.01, 152.85, 136.64,135.20, 129.68, 128.68, 127.67, 127.42, 126.40, 125.91, 125.33, 123.26,121.93, 121.00, 120.61, 120.34, 119.67, 118.56, 112.20, 111.74, 51.72, 50.73.HRMS (ESI): Exact mass calcd for: C 32 H 22 N₂O₄ [M+Na] + : 521.1472, found:521.1468. Example 3: In vitro effects on cancer cell viability I. Materials and Methods 1. Experimental Materials Chronic myeloid leukemia cells (K562), Kunming Cell Bank, Chinese Academy of Sciences; cervical cancer cells (HeLa), Kunming Cell Bank, Chinese Academy of Sciences; gastric adenocarcinoma cells (AGS), Kunming Cell Bank, Chinese Academy of Sciences; DMSO, Shanghai Aladdin Biochemical Technology Co., Ltd.; CCK-8, Zhengzhou Kermite Biotechnology Co., Ltd.; fetal bovine serum, Zhejiang Tianhang Biotechnology Co., Ltd.; RP-1640 medium, Gibco (Thermo Fisher Scientific); PBS, Hangzhou Yifan Xinfu Pharmaceutical Co., Ltd.; trypsin digestion solution, Beijing Solarbio Technology Co., Ltd.
[0042] 2. Experimental apparatus Pipettes (PH24218), Thermo Fisher Scientific, USA; Electronic balance (FA2104N), Shanghai Liangping Instrument Co., Ltd.; Microplate reader (MULTISKAN Sky), Thermo Fisher Scientific, USA; Clean bench (DL-CJ-2NDI), Beijing Donglian Haer Instrument Manufacturing Co., Ltd.; CO2 incubator (3111), Thermo Fisher Scientific, USA; Ultra-low temperature freezer (902GP), Suzhou Thermo Fisher Scientific Technology Co., Ltd.; Cell counting plate (SR10–Countstar), Beijing Haifuda Technology Co., Ltd.; 96-well culture plate, Shanghai Jitai Yikesai Biotechnology Co., Ltd.; Electric thermostatic water bath (DK–S24), Shanghai Jingqi Instrument Co., Ltd.; Wetziar inverted fluorescence microscope (D-35578), Leica Instruments GmbH, Germany; Centrifuge (ST 16R), Thermo Fisher Scientific, USA.
[0043] 3. Experimental Methods (1) Drug concentration setting and grouping: The test compound and the positive control cisplatin were dissolved separately in DMSO to prepare a stock solution with a concentration of 10 mmol / L. The stock solution was then diluted sequentially to five concentrations: 0.5 mmol / L, 0.25 mmol / L, 0.125 mmol / L, 0.0625 mmol / L, and 0.03125 mmol / L, using RP-1640 complete medium.
[0044] (2) Experimental steps: First: Remove the cells in the logarithmic growth phase from the incubator to the ultra-clean workbench, aspirate the original culture medium, wash with PBS 2-3 times, add 1.0 mL of trypsin and place in the incubator for digestion (K562 does not require digestion). After complete digestion, add a small amount of culture medium and then terminate the reaction.
[0045] Second: After repeatedly pipetting, aspirate 10 μL into a counting chamber for counting, and then calculate the amount of cell fluid required for the experiment.
[0046] Third: Add PBS buffer to the outermost ring of the 96-well plate (add blank control complete culture medium to five wells), add cell culture to the remaining empty wells, and incubate the seeded cells at 37 ℃ in a CO2 (5%) environment for 24 hours.
[0047] Fourth: Drug administration. After approximately 24 hours of culture, remove the 96-well plate from the incubator and observe the cell status (if the cells fill all 96 wells and are completely adherent), then discontinue culture. Subsequently, in a clean bench, use a pipette to add 20 µL of the compound solution diluted in RP-1640 complete medium (five concentration gradients: 0.5 mmol / L, 0.25 mmol / L, 0.125 mmol / L, 0.0625 mmol / L, and 0.03125 mmol / L) to each well, and incubate with the cells for 48 h. At this point, the final concentrations of the compound in each well are 100 µmol / L, 50 µmol / L, 25 µmol / L, 12.5 µmol / L, and 6.25 µmol / L, respectively.
[0048] Fifth: CCK-8 treatment. 48 h after drug administration, remove the cell culture medium from each well of the 96-well plate, then add 110 µL of the pre-prepared CCK-8 solution in a dark environment, and continue to incubate in a CO2 incubator for about 1 h.
[0049] Sixth: Absorbance measurement: The CCK-8 reaction was carried out for about 1 hour until the solution turned orange-yellow. Then, the absorbance (OD) value of the solution in each well was measured using a microplate reader at a wavelength of 450 nm.
[0050] (3) Data statistics Based on the OD value measured in the experiment, the inhibition rate was calculated. The specific calculation formula and method are as follows: Inhibition rate (%) = [1 - (OD value)] 给药组均值 –OD 空白组均值 ) / (OD 对照组均值 –OD 空白组均值 The data were analyzed using SPSS (26.0) software to explore the relationship between inhibition rate and compound concentration, thereby obtaining the half-maximal inhibitory concentration (IC50) value of the compound. To ensure the reliability of the experimental results, three parallel experiments were conducted to verify the data and ensure consistency. All experimental indicators are presented as mean ± standard deviation. Student's t-test was used to analyze the differences between groups. If the p-value was less than 0.05, it indicated that the difference between groups was statistically significant.
[0051] II. Experimental Results See Table 1.
[0052] a IC 50 The concentration indicates the concentration of the compound that produced a 50% reduction in cancer cell growth after 48 hours of culture. The values given are the average of three experiments. b Cisplatin was used as a positive control.
[0053] Experimental results showed that in K562 chronic myeloid leukemia cells, one compound (3q) of the chromone bisindole derivatives exhibited inhibitory activity similar to that of the positive control cisplatin, with compound 3q showing superior inhibitory activity compared to the positive control (IC50). 50 = 14.05 ± 0.95 µM). In HeLa cell experiments, seven compounds (3c, 3g, 3h, 3l, 3m, 3o, 3p) showed inhibitory activity close to that of the positive control cisplatin, among which compound 3m (IC50) showed the highest activity. 50 The inhibitory activity of compounds 3c, 3h, and 3l (IC50 ± 0.98 µM) was higher than that of the positive control, and the activity was the best. In the gastric adenocarcinoma AGS assay, the inhibitory effects of compounds 3c, 3h, and 3l on cells were similar to those of the positive control cisplatin, with compound 3h exhibiting the highest activity (IC50 ± 0.98 µM). 50 = 6.70 ± 0.37 µM).
[0054] The above results indicate that, based on the parent nucleus, halogen (Br, Cl, F) substituents are key factors in enhancing activity, and different halogens and substitution positions have varying effects on activity and cell selectivity. Bromine (Br) substitution: Compound 3q (to K562, IC) 50 =14.05 μM), 3o (for HeLa, IC 50 The activity of bromine substitution (19.39 μM) was superior to that of cisplatin (K562: 14.85 μM; HeLa: 19.87 μM), indicating that bromine substitution can enhance the inhibitory activity against K562 and HeLa cells.
[0055] Chlorine (Cl) substitution: Compound 3m's effect on the IC50 of HeLa cells 50 =13.95 μM, which is the strongest activity against HeLa among all tested compounds, indicating that chlorine substitution in this structure has a particularly significant "synergistic effect" on HeLa cells.
[0056] Fluorine (F) substitution: Compound 3h effect on IC50 in AGS cells 50 =6.70 μM, which is far superior to cisplatin (AGS: 10.78 μM), demonstrating the "selective synergistic effect" of fluorine substitution on AGS cells.
[0057] In contrast, compounds without halogen substitution, such as compounds 3a, 3d, and 3k, exhibit extremely weak activity, further demonstrating that halogen substitution is a key modification for enhancing activity.
Claims
1. A chromone bisindole derivative, characterized in that, It has a structure as shown in general formula (Ⅰ): (Ⅰ), Wherein, the R substituent is selected from phenyl, 8-methylphenyl, 7-methylphenyl, 6-methylphenyl, 7-methoxyphenyl, 5-methoxyphenyl, 8-fluorophenyl, 7-fluorophenyl, 6-fluorophenyl, 5-fluorophenyl, 8-chlorophenyl, 7-chlorophenyl, 6-chlorophenyl, 5-chlorophenyl, 8-bromophenyl, 7-bromophenyl, 6-bromophenyl, 6-nitrophenyl, 6,8-dimethylphenyl, 6,7-dimethylphenyl, and naphthyl, and the specific structure corresponds one-to-one with the following structural formulas 3a-3u: 。 2. A method for preparing a chromone bisindole derivative as described in claim 1, characterized in that, Using chromone esters with different benzene ring substitutions as raw materials, their 3-position structure was modified. DCM was used as the solvent and TsOH as the catalyst, and an addition reaction was carried out with indole to obtain chromone bisindole derivatives. The specific steps are as follows: 0.3 mmol of chromone esters with different benzene ring substitutions, 0.9 mmol of indole, and 0.03 mmol of TsOH were added sequentially to a 10 mL reaction flask, followed by 3 mL of DCM. The mixture was stirred at room temperature for 16 hours. Thin-layer chromatography was used to monitor the reaction during the reaction. After the reaction was completed, the chromone bisindole derivatives 3a-3u were obtained by silica gel column chromatography. The synthetic route is as follows: 。 3. The preparation method according to claim 2, characterized in that, The molar ratio of the chromone ester with different benzene ring substitutions, indole, and TsOH is chromone ester with different benzene ring substitutions: indole: TsOH = 1:3:0.
1.
4. The preparation method according to claim 2, characterized in that, The monitored solvent system was a mixture of PE and EA at a volume ratio of 2:
1.
5. The preparation method according to claim 2, characterized in that, The eluent for the silica gel column chromatography purification is a mixture of PE and EA in a volume ratio of 4:
1.
6. The use of a chromone bisindole derivative as described in claim 1 or a chromone bisindole derivative prepared by any one of claims 2-5 in the preparation of antitumor drugs.
7. The application according to claim 6, characterized in that, The anti-tumor drugs mentioned are used to treat leukemia, cervical cancer, or gastric cancer.
